Gate2Brain's pioneering childhood cancer treatment gets EMA orphan drug designation

Gate2Brain, a spin-off company of the SJD Barcelona Children's Hospital that aims to improve the transport of drugs to the brain, has achieved Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its innovative product G2B-002. This is a decisive milestone in the fight against paediatric brain tumours. 

ODD designation is granted to medicines that may be potential treatments for a serious rare disease in the European Union because they offer a significant benefit over limited or no other options.

This ODD recognises G2B-002 as a potential treatment for paediatric brain tumours, a key step in accelerating its progress towards clinical trials for the treatment of paediatric brain tumours.

The patented technology by Gate2Brain enables drugs to cross the blood-brain barrier (BBB) with high precision, thereby increasing both the efficacy and safety of brain tumour treatment.